Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Block

Showing results (461-470 of 488) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
The Lancet. Global Health|May 18, 2023
Sustainable Development Goals summit 2023 and the global pledge on disability-focused early childhood developmentBolajoko O Olusanya, Vivian G Cheung, Mijna Hadders-Algra, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Science Advances|August 24, 2022
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2Haley E Mudrick, Shane Massey, Erin B McGlinch, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 15, 2023
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous CarcinomaChen Wang, Matthew S Block, Julie M Cunningham, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Nature Communications|October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patientsMatthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Pageof 49

Showing results (461-470 of 488) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
The Lancet. Global Health|May 18, 2023
Sustainable Development Goals summit 2023 and the global pledge on disability-focused early childhood developmentBolajoko O Olusanya, Vivian G Cheung, Mijna Hadders-Algra, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Science Advances|August 24, 2022
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2Haley E Mudrick, Shane Massey, Erin B McGlinch, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 15, 2023
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous CarcinomaChen Wang, Matthew S Block, Julie M Cunningham, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Nature Communications|October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patientsMatthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Pageof 49